Generic orforglipron, when it eventually becomes available, could see pricing discounts of 80-90% below brand, following the pattern seen with other generic small molecules
This article aims to provide an overview of GLP-1 based drugs, focusing on semaglutide (marketed as Ozempic for type 2 diabetes and as Wegovy for obesity) and tirzepatide (marketed as Mounjaro), which is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 agonist
Finkel T., RedoxDependent Signal Transduction, FEBS Letters 476 (2000): 5254, 10.1016/s0014-5793(00)01669-0
Related Reading Zepbound For High Cholesterol Tirzepatide For High Cholesterol Wegovy For High Blood Pressure Glp 1 For High Cholesterol Pricing and availability current as of June 2026
First, the marked underutilization of both SGLT2 inhibitors and GLP-1 receptor agonists, despite their well-documented benefits, and the associated reduction in survival underscore the urgent need for healthcare systems and policymakers to implement strategies that promote broader use of these therapies